Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XEPI.
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) vs XEPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
None Documented
None Documented
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion.
Category D/X
Category C
Antibiotic
Antibiotic